Gastric Cancers

>

Latest News

FDA
Pembrolizumab Is Approved for Patients With HER2– Gastric/GEJ Adenocarcinoma

November 16th 2023

The FDA has approved pembrolizumab plus chemotherapy to treat adults with locally advanced or metastatic, HER2-negative gastric cancers.

FDA
New Companion Diagnostic Is Approved to Aid In Gastric Cancer Decision Making

November 15th 2023

FDA
FDA Revisits Pembrolizumab’s Gastric Cancer Indication

November 12th 2023

Patients With Advanced Gastric, Esophageal Cancer Report Better HRQOL Outcomes With Nivolumab-Based Therapy
Patients With Advanced Gastric, Esophageal Cancer Report Better HRQOL Outcomes With Nivolumab-Based Therapy

October 11th 2023

Trastuzumab Deruxtecan Elicits Durable Response in HER2+ Gastric/GEJ Cancer
Trastuzumab Deruxtecan Elicits Durable Response in HER2+ Gastric/GEJ Cancer

July 19th 2023

More News

© 2023 MJH Life Sciences

All rights reserved.